EUCTR2015-003123-57-GB进行中（未招募）1 期
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects with Moderate to Severe Ulcerative Colitis - AMAC
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •(1) have given written informed consent approved by the ERB (ethical review board) governing the site
- •(2) are male or female subjects =18 and =75 years of age at the time of initial screening
- •(2a) Male subjects agree to use a reliable method of birth control during the study and for 3 months, which is greater than 5 half-lives, after the last dose of investigational product. Reliable methods include vasectomy or male condom with spermicide.
- •(2b) female subjects:
- •- are women of childbearing potential whose serum pregnancy test results are negative and who agree to use a reliable method of birth control (eg, condom, sponge, or diaphragm combined with spermicidal foam, gel, or cream; ongoing hormonal contraception [oral, intramuscular, depot, or transdermal], such as Depo-Provera, Evra, or NuvaRing or an intrauterine device during the study and for 3 months after the last dose of the investigational product
- •- are not women of childbearing potential, defined as having: bilateral oophorectomy, tubal ligation, or hysterectomy at least 6 weeks before screening; spontaneous amenorrhea for = 12 months, not induced by a medical condition or medications; or spontaneous amenorrhea for 6 to 12 months and a follicle-stimulating hormone level greater than 40 mIU/mL at screening
- •(3) venous access sufficient to allow blood sampling and IV administration (if applicable), as per the protocol
- •(4) have had a diagnosis of UC for =3 months before baseline (endoscopic evidence corroborated by a histopathology report); a biopsy for a local histopathology evaluation (to obtain a report) can be obtained during the baseline endoscopy procedure if a histopathology report is not available
- •(5) have moderate to severe active UC as defined by a Mayo score of 6 to 12 with an endoscopic subscore =2 within 14 days before the first dose of study treatment (note: a partial Mayo score of at least 4 and other eligibility criteria must have been met before endoscopy is performed as a study procedure)
- •(6) have evidence of UC extending proximal to the rectum (=15 cm of involved colon)
- •(7) have documentation of a surveillance colonoscopy (performed according to local standard) within 12 months before baseline (may be performed during screening) for subjects with pancolitis of >8 years’ duration or left-sided colitis of >12 years’ duration
- •(7a) up-to-date colorectal cancer surveillance (performed according to local standard), for subjects with family history of colorectal cancer, personal history of increased colorectal cancer risk, age >50 years, or other known risk factor
- •(8) subjects must either:
- •(8a) be naive to biologic therapy (such as TNF antagonists, vedolizumab, or experimental UC biologics) and have at least 1 of the following:
- •- inadequate response or failure to tolerate current treatment with oral or IV corticosteroids or immunomodulators (6-MP or AZA) or
- •- history of corticosteroid dependence (an inability to successfully taper corticosteroids without return of UC)
- •(8b) have received treatment with 1 or more biologic agents (such as TNF antagonists, vedolizumab, or experimental UC biologics) with or without documented history of failure to respond or tolerate su
排除标准
- •(12) have been diagnosed with indeterminate colitis, proctitis (distal disease involving the rectum only; less than 15 cm from the anal verge) or CD
- •(13) have had surgery for treatment of UC or are likely to require surgery for UC during the study
- •(14) have received any of the following for treatment of UC:
- •(14a) cyclosporine or thalidomide within 30 days of screening endoscopy
- •(14b) corticosteroid enemas, corticosteroid suppositories, or topical treatment with 5-ASA within 30 days of screening endoscopy
- •(14c) have used apheresis (eg, Adacolumn apheresis) =2 weeks before screening endoscopy
- •(15) have previous exposure to any biologic therapy targeting IL-23 (including ustekinumab), either licensed or investigational
- •(16) have been treated with any investigational drug for UC within 30 days or 5 half-lives of the drug (whichever is longer) before the initial screening visit (Visit 1), OR with interferon therapy within 8 weeks before baseline
- •(17) have evidence of abdominal abscess or toxic megacolon during screening
- •(18) have extensive colonic resection, subtotal or total colectomy, ileostomy, colostomy, or fixed symptomatic stenosis of the intestine
- •(19) have evidence of active or latent TB (refer to Section 10.3.2.2 of the protocol for details on full TB exclusion criteria)
- •(20) have had any malignancy within 5 years of screening, except for basal cell or squamous epithelial carcinoma of the skin that has been resected with no evidence of metastatic disease for at least 3 years OR cervical carcinoma in situ with no evidence of recurrence within 5 years of screening
- •(21) are investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
- •(22) are Lilly employees or employees of third -party organizations (TPOs) involved with the study
- •(23) are currently enrolled in a clinical trial involving an investigational product or nonapproved use of a drug or device, OR are concurrently enrolled in any other type of medical research not scientifically or medically compatible with this study, per investigator judgment
- •(24) have previously completed or withdrawn from this study or any other study investigating LY3074828. This criterion does not apply to subjects undergoing rescreening procedures.
- •(25) have received live, attenuated vaccine(s) within 2 months of screening or intend to receive such during the study; vaccines should be avoided for 2 months after the last dose of study drug. Uses of nonlive (inactivated) vaccinations are allowed for all subjects
- •(26) have HIV/AIDS or test positive for human immunodeficiency virus antibodies at screening
- •(27) have hepatitis B or test positive for hepatitis B virus (HBV) at screening, defined as: (1) positive for hepatitis B surface antigen or (2) positive for anti–hepatitis B core antibody (HBcAb+) and positive confirmatory polymerase chain reaction (PCR) for HBV, regardless of anti–hepatitis B surface antibody status
- •(28) have hepatitis C or test positive hepatitis C virus at screening, defined as: positive result for hepatitis C antibody and posi
研究者
相似试验
进行中（未招募）
1 期
Clinical trial to evaluate the benefit and safety of ST-0529 in subjects who are suffering from active ulcerative colitisActive ulcerative colitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2018-003349-41-BGSublimity Therapeutics (Hold Co) Ltd.380
进行中（未招募）
1 期
To evaluate the efficacy, safety and tolerability of M281 injection for the treatment of patients with Myasthenia gravis, a neuromuscular diseaseTreatment of MG, with an initial focus on patients with gMG treated with M281 injection and evaluation of the expected reduction of circulating levels of antibodies by blocking IgG recycling, including the pathogenic autoantibodies that cause MG, and to ameliorate manifestations of the disease.MedDRA version: 21.1Level: PTClassification code 10028417Term: Myasthenia gravisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2018-002247-28-ITMOMENTA PHARMACEUTICALS, Inc68
进行中（未招募）
1 期
An investigational study to assess the safety and effectiveness of an investigational drug in people with moderate to severe ulcerative colitislcerative colitisMedDRA version: 20.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 100000004856EUCTR2015-003123-57-CZEli Lilly and Company240
进行中（未招募）
2 期
VTX002 versus Placebo for the Treatment of Moderately toSeverely Active Ulcerative ColitisCTRI/2023/03/050181Oppilan Pharma Ltd a wholly owned subsidiary of Ventyx Biosciences Inc
进行中（未招募）
1 期
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab in Adult Subjects with H-1 Antihistamine Refractory Chronic Spontaneous UrticariaChronic spontaneous urticariaMedDRA version: 20.0Level: PTClassification code 10072757Term: Chronic spontaneous urticariaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2022-001847-26-PLAllakos Inc.110